Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Ascletis Pharma, Inc. (1672) Stock Price & Analysis

9 Followers

1672 Stock Chart & Stats

HK$4.31-HK$0.45(-9.36%)
At close: 4:00 PM GMT+8
HK$5HK$7.5HK$10Aug 10Aug 24Sep 7Sep 21Oct 5Oct 20Nov 2
Day’s Range
HKD 4.27 - HKD 4.93
52-Week Range
HKD 4.27 - HKD 19.86
Previous Close
HKD 4.76
Volume
N/A
Average Volume (3M)
2.11M
Market Cap
HKD 5.00B
Enterprise Value
HKD 8.36B
Total Cash (Recent Filing)
HKD 2.27B
Total Debt (Recent Filing)
HKD 3.74M
Price to Earnings (P/E)
―
Beta
1.06
Next Earnings
Mar 30, 2027 (Est.)
EPS Estimate
-0.49
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low debt relative to equity reduces solvency pressure and interest-related cash demands. This gives Ascletis greater flexibility to fund research, sustain commercial activities, or adjust spending while limiting the balance-sheet risk associated with prolonged operating losses.

Integrated Drug Platform

An integrated model spanning discovery, clinical development, and commercialization can retain more value from successful medicines than a narrow research-only approach. In-house capabilities also support continuity across development stages, while collaborations can extend resources and expertise.

Multiple Monetization Routes

Ascletis has several potential ways to monetize its assets rather than relying exclusively on direct product sales. Commercial revenue can be supplemented by milestone payments, royalties, or collaboration income, creating strategic flexibility as pipeline candidates advance.

Bears Say

Revenue Collapse

The sharp drop in revenue indicates substantial deterioration in the current commercial base and leaves the company operating at a very low revenue run-rate. Unless product sales recover or pipeline assets become monetizable, weak scale will continue to limit operating leverage.

Persistent Unprofitability

Persistent losses and the recent move to negative gross profit show that current revenue is not covering the cost base, not merely that earnings are temporarily soft. Continued operating deficits can erode equity and constrain the resources available for long-term development.

Accelerating Cash Burn

Repeatedly negative operating and free cash flow means the business is not self-funding and must absorb substantial ongoing cash outflows. The sharp increase in burn from 2023 raises the importance of disciplined spending and future financing or asset-monetization capacity.

Ascletis Pharma, Inc. News

1672 FAQ

What was Ascletis Pharma, Inc.’s price range in the past 12 months?
Ascletis Pharma, Inc. lowest stock price was HK$4.27 and its highest was HK$19.86 in the past 12 months.
What is Ascletis Pharma, Inc.’s market cap?
Ascletis Pharma, Inc.’s market cap is HK$5.00B.
When is Ascletis Pharma, Inc.’s upcoming earnings report date?
Ascletis Pharma, Inc.’s next earnings report is estimated for Mar 30, 2027 (not yet confirmed), which is in 145 days.
How were Ascletis Pharma, Inc.’s earnings last quarter?
Ascletis Pharma, Inc. released its earnings results on Aug 31, 2026. The company reported -HK$0.359 earnings per share for the quarter, missing the consensus estimate of -HK$0.234 by -HK$0.125.
Is Ascletis Pharma, Inc. overvalued?
According to Wall Street analysts Ascletis Pharma, Inc.’s price is currently Undervalued.
Does Ascletis Pharma, Inc. pay dividends?
Ascletis Pharma, Inc. does not currently pay dividends.
What is Ascletis Pharma, Inc.’s EPS estimate?
Ascletis Pharma, Inc.’s EPS estimate is -0.49.
How many shares outstanding does Ascletis Pharma, Inc. have?
Ascletis Pharma, Inc. has 1,057,987,000 shares outstanding.
What happened to Ascletis Pharma, Inc.’s price movement after its last earnings report?
Ascletis Pharma, Inc. reported an EPS of -HK$0.359 in its last earnings report, missing expectations of -HK$0.234. Following the earnings report the stock price went down -0.792%.
Which hedge fund is a major shareholder of Ascletis Pharma, Inc.?
Currently, no hedge funds are holding shares in HK:1672
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology